Literature DB >> 15113548

Globotriaosylceramide isoform profiles in human plasma by liquid chromatography-tandem mass spectrometry.

Bryant C Nelson1, Thomas Roddy, Shaparak Araghi, Dennis Wilkens, John J Thomas, Kate Zhang, Crystal C-C Sung, Susan M Richards.   

Abstract

Globotriaosylceramide (GL3) is a heterogeneous glycosphingolipid that is elevated in the blood plasma of patients diagnosed with Fabry disease. GL3 consists of numerous isoforms, some of which are distinctly specific to human plasma. An electrospray-ionization LC/MS/MS method has been developed that has the capacity to monitor the GL3 isoform profiles in plasma extracts. Total GL3 is extracted from human plasma via chloroform/methanol liquid-liquid extraction, purified by C(18) solid-phase extraction and analyzed by multiple reaction monitoring LC/MS/MS. The relative responses of eight selected isoforms are calculated on the basis of the total GL3 response and the isoform responses are subsequently utilized to construct isoform profile plots.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113548     DOI: 10.1016/j.jchromb.2004.02.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

1.  Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

Authors:  P D Whitfield; J Calvin; S Hogg; E O'Driscoll; D Halsall; K Burling; G Maguire; N Wright; T M Cox; P J Meikle; P B Deegan
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 2.  Immunologic mapping of glycomes: implications for cancer diagnosis and therapy.

Authors:  Dapeng Zhou; Steven B Levery; Fong-Fu Hsu; Peng G Wang; Susann Teneberg; Igor C Almeida; Yunsen Li; Huaxi Xu; Lai-Xi Wang; Chengfeng Xia; Nuhad K Ibrahim; Katja Michael
Journal:  Front Biosci (Schol Ed)       Date:  2011-06-01

3.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

4.  Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea.

Authors:  Jeong-Yup Kim; Young-Youl Hyun; Ji-Eun Lee; Hye-Ran Yoon; Gu-Hwan Kim; Han-Wook Yoo; Seong-Tae Cho; No-Won Chun; Byoung-Chunn Jeoung; Hwa-Jung Kim; Keong-Wook Kim; Seong-Nam Kim; Yung-A Kim; Hyun-Ah Lee; Jong-Young Lee; Yung-Chun Lee; Hun-Kwan Lim; Keong-Sik Oh; Seong-Hwan Son; Beong-Hee Yu; Kyeong-So Wee; Eun-Jong Lee; Young-Ki Lee; Jung-Woo Noh; Seung-Jung Kim; Kyu-Bok Choi; Suk-Hee Yu; Heui-Jung Pyo; Young-Joo Kwon
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 3.165

5.  Lipidomics of glycosphingolipids.

Authors:  Hany Farwanah; Thomas Kolter
Journal:  Metabolites       Date:  2012-02-02

6.  A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse.

Authors:  Seok-Ho Shin; Min-Ho Park; Jin-Ju Byeon; Byeong Ill Lee; Yuri Park; Ah-Ra Ko; Mi-Ran Seong; Soyeon Lee; Mi Ra Kim; Jinwook Seo; Myung Eun Jung; Dong-Kyu Jin; Young G Shin
Journal:  Pharmaceutics       Date:  2018-06-07       Impact factor: 6.321

7.  A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients.

Authors:  Fahad J Alharbi; Tarekegn Geberhiwot; Derralynn A Hughes; Douglas G Ward
Journal:  J Am Soc Mass Spectrom       Date:  2016-01-21       Impact factor: 3.109

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.